Publications by authors named "Ladislas Capdevila"
Background: Emicizumab is a bispecific, chimeric, humanized immunoglobulin G (IgG)4 that mimics the procoagulant activity of factor (F) VIII (FVIII). Its long half-life and subcutaneous route of administration have been life-changing in treating patients with hemophilia A (HA) with or without FVIII inhibitors. However, emicizumab only partially mimics FVIII activity; it prevents but does not treat acute bleeds.
View Article and Find Full Text PDFArticle Synopsis
- The activated clotting time (ACT) is a test to see how long it takes for blood to clot and is important when using a blood thinner called heparin during heart surgeries or procedures.
- A new medicine called emicizumab helps prevent bleeding in people with hemophilia A and works faster than another medicine, but it doesn’t stop the effects of heparin on ACT.
- The study showed that even with emicizumab, heparin still makes the ACT longer, meaning doctors can still rely on ACT tests to check how well heparin is working for patients using emicizumab during medical procedures.